Clinical Development Programme
The table below indicates trials that concern the investigation of taletrectinib as an inhibitor of TRK activity. Other trials are also ongoing examining its role in ROS inhibition.
Summary of Ongoing Clinical Trials for Taletrectinib
Registry number |
Name |
Phase |
Title |
NCT04617054 |
- |
2 |
Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene |
These data are current as of TBC (https://clinicaltrials.gov)
References
- Katayama R, Gong B, Togashi N et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604.
- Papadopoulos KP, Borazanci E, Shaw AT, et al. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Sep 15;26(18):4785-4794.